MX2011013078A - Nuevos compuestos potentes antisentido anti apolipoproteina b (apob). - Google Patents
Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).Info
- Publication number
- MX2011013078A MX2011013078A MX2011013078A MX2011013078A MX2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A
- Authority
- MX
- Mexico
- Prior art keywords
- apo
- antisense compounds
- potent anti
- hypercholesterolemia
- new potent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101150102415 Apob gene Proteins 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 4
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18638809P | 2009-06-12 | 2009-06-12 | |
| US25309009P | 2009-10-20 | 2009-10-20 | |
| PCT/EP2009/067561 WO2010076248A1 (en) | 2008-12-31 | 2009-12-18 | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
| PCT/EP2010/058278 WO2010142805A1 (en) | 2009-06-12 | 2010-06-14 | New potent anti apob antisense compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011013078A true MX2011013078A (es) | 2012-02-01 |
Family
ID=42541569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013078A MX2011013078A (es) | 2009-06-12 | 2010-06-14 | Nuevos compuestos potentes antisentido anti apolipoproteina b (apob). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9290758B2 (enExample) |
| EP (1) | EP2440215B1 (enExample) |
| JP (1) | JP2012529279A (enExample) |
| CN (1) | CN102802637A (enExample) |
| AU (1) | AU2010258570B2 (enExample) |
| BR (1) | BR112012000214A2 (enExample) |
| CA (1) | CA2764822A1 (enExample) |
| ES (1) | ES2555057T3 (enExample) |
| IL (1) | IL216519A0 (enExample) |
| MX (1) | MX2011013078A (enExample) |
| NZ (1) | NZ596608A (enExample) |
| WO (1) | WO2010142805A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| MX367083B (es) | 2013-06-27 | 2019-08-05 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9). |
| KR20160083876A (ko) * | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| WO2019165067A1 (en) * | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Camk2d antisense oligonucleotides and uses thereof |
| TW202031268A (zh) * | 2018-11-13 | 2020-09-01 | 美商雷格勒斯治療公司 | 用於調節mir-10b 活性之微小rna 化合物及方法 |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| JP4484702B2 (ja) * | 2002-07-19 | 2010-06-16 | メデラ ホールディング アクチェンゲゼルシャフト | コネクタ装置 |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| CA2518475C (en) * | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| WO2004091515A2 (en) * | 2003-04-09 | 2004-10-28 | Alnylam Pharmaceuticals, Inc. | iRNA CONJUGATES |
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA2622583A1 (en) | 2005-09-15 | 2007-03-22 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| WO2008053314A2 (en) | 2006-10-30 | 2008-05-08 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
-
2010
- 2010-06-14 WO PCT/EP2010/058278 patent/WO2010142805A1/en not_active Ceased
- 2010-06-14 MX MX2011013078A patent/MX2011013078A/es active IP Right Grant
- 2010-06-14 BR BR112012000214A patent/BR112012000214A2/pt not_active IP Right Cessation
- 2010-06-14 NZ NZ596608A patent/NZ596608A/en not_active IP Right Cessation
- 2010-06-14 JP JP2012514491A patent/JP2012529279A/ja active Pending
- 2010-06-14 ES ES10724511.0T patent/ES2555057T3/es active Active
- 2010-06-14 EP EP10724511.0A patent/EP2440215B1/en not_active Not-in-force
- 2010-06-14 CN CN2010800257913A patent/CN102802637A/zh active Pending
- 2010-06-14 CA CA2764822A patent/CA2764822A1/en not_active Abandoned
- 2010-06-14 US US13/140,777 patent/US9290758B2/en not_active Expired - Fee Related
- 2010-06-14 AU AU2010258570A patent/AU2010258570B2/en not_active Ceased
-
2011
- 2011-11-22 IL IL216519A patent/IL216519A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120115936A1 (en) | 2012-05-10 |
| CA2764822A1 (en) | 2010-12-16 |
| NZ596608A (en) | 2014-01-31 |
| EP2440215B1 (en) | 2015-10-21 |
| JP2012529279A (ja) | 2012-11-22 |
| AU2010258570B2 (en) | 2016-09-01 |
| WO2010142805A4 (en) | 2011-03-03 |
| US9290758B2 (en) | 2016-03-22 |
| BR112012000214A2 (pt) | 2018-06-19 |
| EP2440215A1 (en) | 2012-04-18 |
| ES2555057T3 (es) | 2015-12-28 |
| IL216519A0 (en) | 2012-02-29 |
| CN102802637A (zh) | 2012-11-28 |
| WO2010142805A1 (en) | 2010-12-16 |
| AU2010258570A1 (en) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1062I2 (fr) | Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide | |
| TR201909777T4 (tr) | Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar | |
| WO2010135703A3 (en) | Endoxifen methods and compositions in the treatment of mammalian diseases | |
| EP2443238A4 (en) | TREATMENT OF ILLNESSES RELATED TO PARAOXONASE 1 (PON1) BY INHIBITION OF THE NATURAL ANTISENSE TRANSCRIPT AGAINST PON 1 | |
| WO2013074974A3 (en) | Modified rnai agents | |
| EP2192911B8 (de) | Pflanzenextrakt aus thc-armen cannabis zur behandlung von erkrankungen | |
| WO2012177784A3 (en) | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof | |
| CR11272A (es) | Enzimas de aciltranferasa de lecitina-colesterol, modificadas | |
| SG10201801321XA (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| BR112013024122A2 (pt) | compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso | |
| WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| MX2013009191A (es) | Oligonucleotidos antisentido. | |
| NZ615578A (en) | Pyridopyrazine derivatives and their use | |
| BR112015032432A2 (pt) | Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro | |
| MX2010006039A (es) | Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica. | |
| PH12014500967A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| BR112012013710A2 (pt) | processos para a preparação de deferasirox e polimorfos de deferasirox. | |
| MY157237A (en) | Azetidinone compounds and medical use thereof | |
| WO2010142805A4 (en) | New potent anti apob antisense compounds | |
| WO2010102154A3 (en) | Biaryl oxyacetic acid compounds | |
| WO2013078376A3 (en) | Isoxazole treatments for diabetes | |
| AU2011263493A8 (en) | Crystalline forms of thalidomide and processes for their preparation | |
| CO6630197A2 (es) | Nuevos procesos | |
| PH12013501665A1 (en) | Cathepsin c inhibitors | |
| MX2012007080A (es) | [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(1h-pirrolo-pi ri-din-il)-metanonas y sintesis de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |